Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
40,378 results
  • Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors. [Journal Article]
    Br J Haematol. 2023 Feb 06 [Online ahead of print]Jing CB, Prutsch N, … Look AT
  • TET2 inactivating mutations serve as initiating genetic lesions in the transformation of haematopoietic stem and progenitor cells (HSPCs). In this study, we analysed known drugs in zebrafish embryos for their ability to selectively kill tet2-mutant HSPCs in vivo. We found that the exportin 1 (XPO1) inhibitors, selinexor and eltanexor, selectively kill tet2-mutant HSPCs. In serial replating colony…
  • Immune therapy: a new therapy for acute myeloid leukemia. [Review]
    Blood Sci. 2023 Jan; 5(1):15-24.Tian C, Chen Z
  • Although complete remission could be achieved in about 60%-70% of acute myeloid leukemia (AML) patients after conventional chemotherapy, relapse and the state of being refractory to treatment remain the main cause of death. In addition, there is a great need for less intensive regimens for all medically frail patients (both due to age/comorbidity and treatment-related). Immune therapy anticipates…
  • Renal Angiomyolipoma Causing Inferior Vena Cava Thrombus in a Young Girl With Tuberous Sclerosis. [Case Reports]
    Cureus. 2023 Jan; 15(1):e33244.Buksh O, Khogeer A, … Junaid I
  • Angiomyolipomas (AML), also known as hamartomas, are benign mesenchymal tumors of the kidneys which consist of vascular tissue, smooth muscles, and adipose tissue, with a higher prevalence in females than males. AML may be associated with tuberous sclerosis, and the growth of the mass may present as hematuria or flank pain. We present a case of a 14-year-old female patient who had a known case of…
  • Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia. [Journal Article]
    Leukemia. 2023 Feb 04 [Online ahead of print]Larrue C, Mouche S, … Tamburini J
  • Mitochondrial metabolism recently emerged as a critical dependency in acute myeloid leukemia (AML). The shape of mitochondria is tightly regulated by dynamin GTPase proteins, which drive opposing fusion and fission forces to consistently adapt bioenergetics to the cellular context. Here, we showed that targeting mitochondrial fusion was a new vulnerability of AML cells, when assayed in patient-de…
  • mRNA-lncRNA gene expression signature for predicting pediatric AML relapse. [Journal Article]
    Curr Res Transl Med. 2023 Jan 25; 71(2):103379.Kulaeva ED, Mashkina EV
  • Children with acute myeloid leukemia (AML) face a relapse of the disease in 30% of all cases. AML relapse is difficult to predict, and existing risk scales are often ineffective. Using data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET-AML) project, we defined an expression signature based on matrix RNAs (mRNAs) and long non-coding RNAs (lncRNAs) that could…
  • Molecular genetics and management of world health organization defined atypical chronic myeloid leukemia. [Journal Article]
    Ann Hematol. 2023 Feb 03 [Online ahead of print]Sun Y, Wang Q, … Chen S
  • Atypical chronic myeloid leukemia (CML) is a rare BCR::ABL1-negative hematopoietic stem cell disease characterized by granulocytic proliferation and granulocytic dysplasia. Due to both the challenging diagnosis and the rarity of atypical CML, comprehensive molecular annotation-based analyses of this disease population have been scarce, and it is currently difficult to identify the optimal treatme…
  • Younger Haploidentical Donor Versus Older Matched Unrelated Donor for Patients With AML/MDS. [Journal Article]
    Am J Hematol. 2023 Feb 02 [Online ahead of print]Marcoux C, Marin D, … Mehta RS
  • Optimal donor selection is fundamental to successful allogeneic hematopoietic cell transplantation (HCT), and donor age influences survival after both matched unrelated donor (MUD) and haploidentical donor HCT. Though recent studies have shown similar outcomes between MUD and haploidentical HCT, it is unknown if outcomes differ following HCT with younger haploidentical donors compared to HCT with…
New Search Next